Editing N-Ethyltryptamine

{{Short description|Chemical compound}}
{{DISPLAYTITLE:''N''-Ethyltryptamine}}
{{Drugbox
| verifiedrevid = 447115197
| drug_name = ''N''-Ethyltryptamine
| image = N-Ethyltryptamine.png
| width = 200px

<!--Clinical data-->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| routes_of_administration = 
| ATC_prefix = None
| ATC_suffix = 

<!--Legal status-->
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = [[List of Schedule I drugs|Schedule I (isomer of DMT)]]
| legal_status = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 61-53-0
| PubChem = 6092
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5867
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = M6X6KY3BQH
| synonyms = NET; NETP; Ethyltryptamine

<!--Chemical data-->
| IUPAC_name = ''N''-ethyl-2-(1''H''-indol-3-yl)ethan-1-amine
| C=12 | H=16 | N=2 
| SMILES = CCNCCc1c[nH]c2ccccc12
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H16N2/c1-2-13-8-7-10-9-14-12-6-4-3-5-11(10)12/h3-6,9,13-14H,2,7-8H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = TZWUSTVNAVKAPA-UHFFFAOYSA-N

<!--Physical data-->
| melting_point = 87
| melting_high = 88
}}

'''''N''-Ethyltryptamine''' ('''NET''') is a [[substituted tryptamine|tryptamine]] that is [[structural analog|structurally related]] to [[N-methyltryptamine|''N''-methyltryptamine]] (NMT) and the [[psychedelic drug]]s [[N,N-dimethyltryptamine|''N'',''N''-dimethyltryptamine]] (DMT) and [[diethyltryptamine|''N'',''N''-diethyltryptamine]] (DET).<ref name="TiHKAL">[http://www.erowid.org/library/books_online/tihkal/tihkal49.shtml NET Entry in ''TIHKAL'']</ref>

It has been found to act as a [[potency (pharmacology)|potent]] [[serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[full agonist]] and [[serotonin releasing agent]].<ref name="BloughLandavazoDecker2014">{{cite journal | vauthors = Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB | title = Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes | journal = Psychopharmacology (Berl) | volume = 231 | issue = 21 | pages = 4135–4144 | date = October 2014 | pmid = 24800892 | pmc = 4194234 | doi = 10.1007/s00213-014-3557-7 | url = }}</ref>

[[Alexander Shulgin]] included NET as an entry in ''[[TiHKAL]]''.<ref name="TiHKAL" /> However, he stated that it had been subjected only to modest human trials and that no active dose level had been identified.<ref name="TiHKAL" />

== See also ==
* [[N-Methyltryptamine|''N''-Methyltryptamine]] (NMT)
* [[N,N-Dimethyltryptamine|''N'',''N'',-Dimethyltryptamine]] (DMT)

== References ==
{{Reflist}}

{{Serotonin receptor modulators}}
{{Monoamine releasing agents}}
{{Tryptamines}}

{{DEFAULTSORT:Ethyltryptamine, N-}}

[[Category:5-HT2A agonists]]
[[Category:N-Monoalkyltryptamines]]
[[Category:Serotonin receptor agonists]]
[[Category:Serotonin releasing agents]]